New Oral SERD Vepdegestrant Shows Promise in ESR1 Mutated Breast Cancer Patients

追加: 2026-05-05

[00:00:00]8.6 months. There is a kind of sibling trial that is very tac a phase three trial that looked at a different agent not exactly an oral third but a proac an agent that degrades the estrogen receptor in a different way vagastrant compared to sound of care endocrine therapy. In the trial verit also phase three they enrolled patients that were a little less protreated without prior chemotherapy and here there was a significant improvement in outcomes in the ESA1 mutated population but not in the overall population and this trial didn't lead to an approval yet but we expect that it will lead to an additional agent being available in clinical practice. Toxicity wise, both elestrant and vetoastrant were very well tolerated, which is a good thing about oral thirds. A tiny bit of nausea with elicester is observed. Some QTC prolongation with epagrant, but very low grade and low rate with both of them. So overall, two trials that are bringing new agents to practice.

[00:01:00]>> Yeah, for sure. Very exciting time.

[00:01:02]>> Let's move next.

[00:01:03]>> Yep. So next, uh, we're going to have a triple header. All right.